FimmCyte
Develops a non-hormonal, disease-modifying treatment for late-stage endometriosis by targeting and eliminating tissue overexpressing a specific protein found only in endometriosis cells. This approach addresses the lack of effective, targeted therapies for a condition that significantly impacts patients' quality of life. Preclinical studies demonstrate high efficacy in both patient samples and animal models.
- Biotechnology
Funding
Raised to date
$1.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Endometriosis, a chronic fibro-inflammatory disease, lacks effective, disease-modifying treatments, leaving patients with limited options that primarily address symptoms rather than the root cause. Current therapies often involve hormonal treatments, which can have significant side effects and do not eliminate the diseased tissue. This results in a substantial unmet need for targeted therapies that can improve long-term outcomes and quality of life for those affected.
Solution
FimmCyte is developing a first-in-class immunotherapy designed to selectively eliminate diseased tissue in late-stage endometriosis. The treatment targets a specific protein that is overexpressed in endometriosis cells compared to healthy tissue, enabling precise removal of fibrotic tissue without affecting healthy areas. This approach holds the potential to be a disease-modifying treatment, addressing the underlying cause of endometriosis rather than just managing symptoms. Preclinical studies have demonstrated high efficacy in patient samples and animal models, showing promising antifibrotic effects.
Target Audience
The primary target audience includes women suffering from late-stage endometriosis, as well as healthcare providers specializing in women's health and seeking more effective, targeted treatment options.
Features
- Targeted immunotherapy platform designed to eliminate diseased tissue without affecting healthy areas.
- Treatment based on the discovery of a specific protein overexpressed in endometriosis cells.
- Demonstrated antifibrotic effects in preclinical studies using patient samples and animal models.
- Aims to provide a disease-modifying treatment option for late-stage endometriosis.